Logo BizupsLogo Bizups
    • Investors
    • Accelerators
    • Incubators
    • Startups

      Investor posts

      • Home
      • Posts
      • Investor
      Georgian
      Purpose Report 2023
      • . Nov. 17, 2024, 11:36 p.m.

      Purpose Report 2023

      Georgian
      Why Georgian Invested in Armis (Again)
      • . Nov. 17, 2024, 11:36 p.m.

      Why Georgian Invested in Armis (Again)

      Georgian
      Why Georgian Invested in Glooko (Again)
      • . Nov. 17, 2024, 11:36 p.m.

      Why Georgian Invested in Glooko (Again)

      Georgian
      Why Georgian Invested in You.com
      • . Nov. 17, 2024, 11:36 p.m.

      Why Georgian Invested in You.com

      Georgian
      Why Georgian Invested in Coder
      • . Nov. 17, 2024, 11:36 p.m.

      Why Georgian Invested in Coder

      Georgian
      Why Georgian is Investing in SurrealDB
      • . Nov. 17, 2024, 11:36 p.m.

      Why Georgian is Investing in SurrealDB

      Georgian
      Redefining Legal Impact with the Team at Darrow
      • . Nov. 17, 2024, 11:36 p.m.

      Redefining Legal Impact with the Team at Darrow

      Georgian
      Testing LLMs for Trust and Safety
      • . Nov. 17, 2024, 11:36 p.m.

      Testing LLMs for Trust and Safety

      Georgian
      Introducing Georgian’s “Crawl, Walk, Run” Framework for Adopting Generative AI
      • . Nov. 17, 2024, 11:36 p.m.

      Introducing Georgian’s “Crawl, Walk, Run” Framework for Adopting …

      Georgian
      How AI is Redefining Coding
      • . Nov. 17, 2024, 11:36 p.m.

      How AI is Redefining Coding

      Lumira Ventures
      Thryv Therapeutics Completes Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 – Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025
      • . Nov. 15, 2024, 8:46 p.m.

      Thryv Therapeutics Completes Phase 1 Dosing of its …

      Lumira Ventures
      COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
      • . Nov. 11, 2024, 6:46 p.m.

      COUR Pharmaceuticals Announces Positive Top-line Results from Phase …

      Lumira Ventures
      Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients
      • . Nov. 11, 2024, 6:46 p.m.

      Thryv Therapeutics Receives Positive Top-Line Results from Wave …

      Lumira Ventures
      Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment
      • . Nov. 11, 2024, 6:46 p.m.

      Thryv Therapeutics Granted FDA Orphan Drug Designation for …

      Lumira Ventures
      COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives
      • . Nov. 11, 2024, 6:46 p.m.

      COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth …

      Lumira Ventures
      COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors
      • . Nov. 11, 2024, 6:46 p.m.

      COUR Pharmaceuticals Appoints Tim Walbert to its Board …

        • 7
        • 8
        • 9
        • 10
        • 11
        • 12
        • 13
        • 14
        • 15

      Search Posts

      Categories

        Last Posts

          Logo Bizups

          Uncover the Startup Ecosystem

          • [email protected]

          Links

          • Investors
          • Accelerators
          • Incubators
          • Startups

          Links

          • Programs
          • Events
          • Mentors
          • Posts
          • Live

          Support

          • About Us
          • User Guide
          • Disclaimer
          • Privacy Policy
          • Contact Us

          Social Media

          © Bizups.info. All rights reserved.
          Login
          Sign In/Sign Up with linkedin
          Signup

          Your signup was successful. To complete the process of registering your first name, please refer to your email and confirm the email received from us.

          We found a number of people with your first name. When you find your first name in this list, select it

          This section is for the registration of real people's first name, it will be canceled in case of registration with name/organization or startup profile. After registering First name, you can add and manage your startup.Entering all requested information is mandatory